Gene · 9476
Papers2,888
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,888
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer. | Anticancer Res | 2024 | 38307593 | PubTator, text mining | PubMed |
| Mutually exclusive driver mutations identifies 2 separate primaries in a collision tumor initially interpreted as a solitary lung adenocarcinoma with tumor heterogeneity. | Respir Med Case Rep | 2024 | 38304116 | PubTator, text mining | PubMed |
| Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. | iScience | 2024 | 38303720 | PubTator, text mining | PubMed |
An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment. | Heliyon | 2024 | 38298673 | PubTator, text mining | PubMed |
| The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma. | BMC Cancer | 2024 | 38287300 | PubTator, text mining | PubMed |
| Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report. | Onco Targets Ther | 2024 | 38283732 | PubTator, text mining | PubMed |
| [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases]. | Zhonghua Bing Li Xue Za Zhi | 2024 | 38281780 | PubTator, text mining | PubMed |
| Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report. | Medicine (Baltimore) | 2024 | 38277579 | PubTator, text mining | PubMed |
| Characteristics of renal pathology and coagulation function in IgA nephropathy and IgA vasculitis associated nephritis. | BMC Nephrol | 2024 | 38273279 | PubTator, text mining | PubMed |
| Multi-omics integration reveals a nonlinear signature that precedes progression of lung fibrosis. | Clin Transl Immunology | 2024 | 38269243 | PubTator, text mining | PubMed |
| SERS sensing for cancer biomarker: Approaches and directions. | Bioact Mater | 2024 | 38260819 | PubTator, text mining | PubMed |
| Atypical Histopathological Aspects of Common Types of Lung Cancer-Our Experience and Literature Review. | Medicina (Kaunas) | 2024 | 38256374 | PubTator, text mining | PubMed |
| An Overview of Advances in Rare Cancer Diagnosis and Treatment. | Int J Mol Sci | 2024 | 38256274 | PubTator, text mining | PubMed |
| Rare axillary cancer of unknown primary originating from the breast of a 64‑year‑old male patient: A case report and literature review. | Oncol Lett | 2024 | 38249810 | PubTator, text mining | PubMed |
| Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. | Cell Commun Signal | 2024 | 38233864 | PubTator, text mining | PubMed |
| Human pluripotent stem cell modeling of alveolar type 2 cell dysfunction caused by ABCA3 mutations. | J Clin Invest | 2024 | 38226623 | PubTator, text mining | PubMed |
| The differential diagnosis of lung precursor glandular lesions, micro-invasive adenocarcinoma, and invasive adenocarcinoma using low dose spectral computed tomography perfusion imaging. | Quant Imaging Med Surg | 2024 | 38223102 | PubTator, text mining | PubMed |
| Whether specific genetic feature predicted immunotherapy efficacy: A case report. | Medicine (Baltimore) | 2024 | 38215117 | PubTator, text mining | PubMed |
| A case report of challenges in distinguishing gastroesophageal junction hepatoid adenocarcinoma from testicular germ cell tumor: Insights for improved diagnosis with gene expression profiling. | SAGE Open Med Case Rep | 2024 | 38187811 | PubTator, text mining | PubMed |
| Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma. | Clin Proteomics | 2024 | 38182978 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9476/papers?page=13